[{"type": "title", "data": "COVID-19 Baricitinib (Version 2.32)"}, {"type": "category", "data": "Medications"}, {"type": "note", "data": "Patients admitted to hospital for more than 14 days with symptoms of COVID-19 should NOT receive&nbsp;baricitinib for COVID-19 "}, {"type": "note", "data": "Inclusion criteria:Patient requires oxygen supplementation above baseline requirementsORPatient requires life support because of suspected or confirmed COVID-19 (when tocilizumab is NOT available), including:- high-flow oxygen support (e.g., Optiflow) with flow rate greater than 30 L/min and FiO2 greater than 0.4OR- invasive or non-invasive mechanical ventilation OR- vasopressor or inotropic support"}, {"type": "note", "data": "Administer within 24 hours of requiring oxygen supplementation above baseline requirements or initiation of life support measures "}, {"type": "note", "data": "Exclusion Criteria - Do NOT use baricitinib if:- ANC is less than 1 x 10^9/L- Lymphocytes is less than 0.2 x 10^9/L- ALT or AST is greater than 5 times the upper limit normal. Note: use caution if 3 to 5 times upper limit normal- Estimated GFR is 15 mL/min or less, or receipt of renal replacement therapy- Active serious infection other than COVID-19 (e.g. suspected or confirmed TB)- Known condition or treatment resulting in ongoing immune suppression including neutropenia prior to hospitalization- Receipt of one or more doses of interferon, rituximab, anakinra, tocilizumab, or sarilumab during this hospitalization or on long-term therapy- Previous use of convalescent plasma or intravenous immunoglobulin for COVID-19 "}, {"type": "note", "data": "Duration of treatment: 14 days or until discharge (whichever sooner).If patient has clinically improved and returned to baseline oxygen requirements, consideration can be given for a shorter treatment duration at prescribers' discretion"}, {"type": "note", "data": "For patients with GFR 60 mL/min or greater"}, {"type": "order", "data": "baricitinib", "value": ""}, {"type": "sentence", "data": "4 mg, PO, Tab, Daily, 14 day(s)"}, {"type": "sentence", "data": "4 mg, via NG tube, Tab, Daily, 14 day(s)"}, {"type": "note", "data": "For patients with GFR 30 to 59 mL/min "}, {"type": "order", "data": "baricitinib", "value": ""}, {"type": "sentence", "data": "2 mg, PO, Tab, Daily, 14 day(s)"}, {"type": "sentence", "data": "2 mg, via NG tube, Tab, Daily, 14 day(s)"}, {"type": "note", "data": "For patients with GFR 15 to 29 mL/min "}, {"type": "order", "data": "baricitinib", "value": ""}, {"type": "sentence", "data": "2 mg, PO, Tab, q2Days, 14 day(s)"}, {"type": "sentence", "data": "2 mg, via NG tube, Tab, q2Days, 14 day(s)"}]
